Azienda Ospedaliera
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MONTESARCHIO, VINCENZO
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
07/27
06/29
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
NCT06270602: The ONCOCAMP Study

Recruiting
N/A
15000
Europe
Data collection (retrospective), Data collection (prospective)
National Cancer Institute, Naples
Oncology
01/25
07/26
PROFTC-I, NCT03473379: Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy

Recruiting
N/A
440
Europe
National Cancer Institute, Naples
Cancer
02/24
07/24
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MONTESARCHIO, VINCENZO
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
07/27
06/29
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
NCT06270602: The ONCOCAMP Study

Recruiting
N/A
15000
Europe
Data collection (retrospective), Data collection (prospective)
National Cancer Institute, Naples
Oncology
01/25
07/26
PROFTC-I, NCT03473379: Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy

Recruiting
N/A
440
Europe
National Cancer Institute, Naples
Cancer
02/24
07/24
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options